share_log

Exscientia Says EXS4318 Drug Candidate Has Entered Phase 1 Clinical Trials in US -- Shares Rise

Exscientia Says EXS4318 Drug Candidate Has Entered Phase 1 Clinical Trials in US -- Shares Rise

認真說 EXS4318 候選藥物已進入美國的 1 期臨床試驗--股價上漲
MT Newswires ·  2023/02/02 11:16

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論